- Global Pharma News & Resources

Cancer Metabolism Based Therapeutics Market 2019 Size, Share, Trends, Comprehensive Research, Significant Portion, analysed By Drug, Indication, End User and Global Companies Forecast to 2026

Cancer Metabolism-based Therapeutics Market – Insights

Cancer metabolism refers to alteration of metabolism of glucose and glutamine by cancer cells for the synthesis of lipids, nucleotides, fatty acids, and proteins. This in turn helps cancer cells to multiply rapidly, which later inhibits various metabolic pathways such as the citric acid cycle, glucose, mitochondrial respiration, and glutamine utilization. According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This in turn demonstrated that heterogeneity is developed at cellular level, which promotes growth of cancerous cells due to increased metabolism rate. The number of available therapies for the treatment of cancer metabolism is limited, which is expected to offer lucrative growth opportunities for the market players.

Get Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Cancer Metabolism Based Therapeutics,

Global Cancer Metabolism-based Therapeutics Market Taxonomy

The global cancer metabolism-based therapeutics market is segmented into:

By Drug:

  • CPI-613
  • Enasidenib

By Indication:

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndromes (MDS)
  • Metastatic Renal Cell Carcinoma
  • Melanoma
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Cancer Metabolism-based Therapeutics Market: Drivers

Increasing R&D in target-based therapies is expected to boost growth of the global cancer metabolism-based therapeutics market. For instance, in 2017, Rafael Pharmaceuticals introduced a breakthrough drug, CPI-613 – an anti-cancer compound – Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is in phase II clinical trial. The U.S. Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael Pharmaceuticals intends to apply for orphan drug designation for CPI-613 for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in the near future. Moreover, in August 2017, Celgene Corporation and Agios Pharmaceutical announced that the U.S. FDA approved New Drug Application (NDA) for enasidenib – a first-in-class drug expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation – in oral form. The U.S. FDA granted the NDA as a priority review for cancer metabolism drug. In 2017, Calithera Biosciences, Inc. developed CB–839 – a novel cancer therapeutic drug. The U.S. FDA granted fast track designation to CB-839 in combination with everolimus for the treatment of metastatic renal cell carcinoma. CB-839 is in phase I and II clinical trials for the treatment of solid tumors non-small cell lung cancer, renal cell carcinoma, melanoma, and triple negative breast cancer.

Furthermore, increasing prevalence of cancer is expected to boost growth of the market. For instance, according to the American Cancer Society (ACS), around 53,670 people are expected be diagnosed with pancreatic cancer and around 43,090 are expected to be recorded due to pancreatic cancer in the U.S in 2017. According to the same source, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, around 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths occurred in 2014. According to National Cancer Institute, in the U.S, around 21,380 (1.3%) new cases and around 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017.

Browse Research Report:

Cancer Metabolism-based Therapeutics Market: Competitive Landscape 

Key players operating in the global cancer metabolism-based therapeutics market include Agios Pharmaceutical, Rafael Pharmaceuticals, Calithera Biosciences, Inc., Celgene Corporation, 3-V Biosciences, and AstraZeneca.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 04-Aug-2020